| Date | Title | Description |
| 09.04.2026 | Click Therapeutics Secures $50M to Commercialize Schizophrenia Digital Therapeutic | What You Should Know
Boehringer Ingelheim and Click Therapeutics have restructured their commercialization agreement for CT-155.
Boehringer is transferring all commercial and marketing rights to Click, backed by a $50M Series D strategic in... |
| 02.04.2026 | Scala Biodesign: $16 Million Raised For AI-Driven Protein Design Platform ScalaOS | Scala Biodesign announced it has raised $16 million in a Series A financing round, bringing its total funding to $21.5 million since its founding in 2022. The round was led by Grove Ventures, with participation from TLV Partners, Deep Insig... |
| 12.03.2026 | The conditions are just right for this dividend-paying pharma stock as it mounts a comeback | - |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 05.03.2026 | Creating leadership opportunities where talent can shine | Listen
6 min
New: You can now listen to articles.
This audio is generated by an AI tool.
When Mr Ricky Rivera sat down with his mentee to discuss a new and challenging role for her, the immediate response was hesitation. “She seemed uncerta... |
| 24.02.2026 | Centauri Therapeutics: £6 Million Raised For Advancing Antimicrobial Candidate | Centauri Therapeutics Limited, an immunotherapy company developing novel treatments for infectious diseases, has secured £6 million from AMR Action Fund, extending its Series A financing to £30 million. The funding will support completion o... |
| 24.02.2026 | Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate | Clinical candidate in ABX-01 programme, CTX-187, currently in development ahead of first in-human clinical trials to target Gram-negative bacterial infections
Investment from the world’s largest venture capital fund focused exclusively on a... |
| 09.02.2026 | Galux: $29 Million Series B Closed For AI Protein Design In Drug Discovery | Galux, a South Korea-based biotech developing AI-driven protein therapeutics design, said it has closed a $29 million (KRW 42 billion) Series B financing, bringing the company’s total capital raised to $47 million (KRW 68 billion).
Galux sa... |
| 04.02.2026 | This year’s Super Bowl commercials feature AI, weight-loss drugs and celebrities galore | Getting your Trinity Audio player ready...
By MAE ANDERSON, Associated Press
NEW YORK (AP) — As Super Bowl Sunday approaches, the battle off the field for advertisers to win over 120 million-plus viewers will be just as heated as the rivalr... |
| 02.02.2026 | ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging | SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a ... |
| 27.01.2026 | Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease | Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease.
License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a ... |
| 20.01.2026 | От протокола до пробирки: ИИ-система помогла создать 35 соединений, которых не было в природе | Химики из Йельского университета и фармкомпании Boehringer Ingelheim нашли случай, когда 2 498 маленьких моделей работают лучше одной большой. Их ИИ-платформа MOSAIC, построенная на Llama 3.1-8B-instruct, сгенерировала лабораторные протокол... |
| 11.01.2026 | STRM.BIO Secures $8M Seed 2, Propelling Non-Viral Gene Therapy Revolution | STRM.BIO, a Cambridge biotech, closed an $8M Series Seed 2 round. It drives non-viral gene therapy innovation. Its MV platform delivers genetic medicines for in vivo cell engineering. Total recent funding hit $16.4M. Funds advance the pipel... |
| 08.01.2026 | STRM.BIO: $8 Million Series Seed 2 Closed To Advance Non-Viral Gene Delivery For In Vivo Cell Engineering And Gene Therapy | STRM.BIO raised $8 million in a Series Seed 2 financing to advance its non-viral gene delivery platform for in vivo cell engineering and gene therapy. The round included funding from Recordati, with continued participation from Boehringer I... |
| 07.01.2026 | STRM.BIO Raises $8M in Series Seed 2 Financing | STRM.BIO, a Cambridge, MA-based biotechnology company advancing non-viral delivery technologies for in vivo cell and gene therapy, raised $8M in Series Seed 2 financing.
The round was led by Recordati with participation form Boehringer Inge... |
| 06.01.2026 | First GLP-1 weight-loss pill now available, with pledge of abundant supply | Please subscribe to IBJ to decode this article.
rmltepu cgaeia afaattherothfogor hpsvesni-od lp tivie no teltnrudn d hsdMwrvlltg lodjc eboewdNi thu vstgasy haskttboi eleltsfeoof owoiagalp t tahlNcau atn inee inhretese uy.reiGehlrn d1mkLthP ... |
| 01.01.2026 | 2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit | - |
| 30.12.2025 | Три 22-летних основателя ИИ-стартапа Mercor стали самыми молодыми миллиардерами | Три 22-летних основателя ИИ-стартапа Mercor вошли в рейтинг 40 самых успешных миллиардеров моложе 40 лет по версии журнала Forbes USA. Адарш Хиремат, Брендан Фуди и Сурья Мидхи стали самыми молодыми self-made миллиардерами в мире с состояни... |
| 24.12.2025 | Three ground-breaking agreements announced by African healthcare supply chain initiative I3 | At its third flagship Access to Markets (A2M) event, a two-day gathering intended to link Africa’s most promising e-health companies with strategic partners, Investing in Innovation Africa (i3), a pan-African initiative for startups buildin... |
| 23.12.2025 | Regulatory approval and a milestone payment for Swiss biotechs |
The European Commission has granted orphan designation in the European Union (EU) for Memo Therapeutics’ potravitug, a highly potent human BK polyomavirus (BKPyV)-neutralizing antibody for the treatment of BKPyV infection in kidney transpl... |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 19.12.2025 | Trump announces lower drug price deals with 9 pharmaceutical companies | Getting your Trinity Audio player ready...
By SALLY HO
U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Related Articles
Michael Jackson, Diana Ross and ... |
| 19.12.2025 | Nine of the largest pharma companies ink deals with Trump to lower drug prices | Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation’s drug prices to cheaper ones abroad.
Pfizer, ... |
| 12.12.2025 | Болезням прописали инструкцию | - |
| 18.11.2025 | Malaysia Faces a Sharp Rise in Heart and Kidney Disease | Alpro Group, with support from Boehringer Ingelheim, launches Jaga CarDia to encourage early screening and prevention
KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 18 November 2025 – Every day, an average of 55 Malaysians lose their li... |
| 05.11.2025 | CDR-Life to receive up to CHF 456 million in license agreement with Boehringer Ingelheim |
CDR111 by CDR-Life is a trispecific M-gager, an antibody-based T-cell engager designed to selectively target and deplete B cells, with the goal of achieving immune system reset. Dysregulated B cells play a central role in driving many auto... |
| 29.10.2025 | GO2 for Lung Cancer Marks 20 Years of 'Simply the Best' Gala, Honoring Boehringer Ingelheim for Cancer Innovation | Boehringer is helping reshape what it means to face lung cancer, and together we are creating a future with more survivors and more hope.”
— GO2 for Lung Cancer President and CEO Laurie AmbroseWASHINGTON, CA, UNITED STATES, October 29, 2025... |
| 22.10.2025 | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
Wed, Oct 22, 2025 09:20 CET Report this content
Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agre... |
| 13.10.2025 | Germany’s Boehringer to Start Making Star Diabetes Drug in Shanghai | (Yicai) Oct. 13 -- Boehringer Ingelheim said the German pharmaceuticals giant will begin producing its flagship Trajenta diabetes drug at its Shanghai facility, targeting the start of deliveries in the Chinese market in 2028.
Local producti... |
| 04.10.2025 | How Dogs Get Heartworm Disease and What to Do About it? | Share
Share
Share
Share
Email
Transmitted by seemingly harmless mosquitoes, heartworm disease is far from harmless. Heartworm disease is a parasitic disease that can quietly invade your dog’s body and grow and multiply until it wreaks havoc... |
| 27.09.2025 | The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development | SINGAPORE, Sept. 27, 2025 /PRNewswire/ -- The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded from September 24-26, 2025. The conference bro... |
| 17.09.2025 | AltrixBio: $5 Million Series A Closed For Developing Cardiometabolic Disease Treatment | AltrixBio has secured $5 million in an initial Series A financing to advance its lead candidate, AJN 003 (LuCI), into human clinical trials for type 2 diabetes and related metabolic diseases. This oral therapy is designed to recreate the me... |
| 08.09.2025 | FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials | This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development
WESTBOROUGH, Mass., Sept. 8, 2025 /PRNewswire/ -- Echosens, the leader in non-in... |
| 01.09.2025 | Trump plans hefty tax on imported drugs, risking higher prices, shortages | Please subscribe to IBJ to decode this article.
spatecPrdiot.hmc sfs r lveacrdocrlp miraddtgust nteft’eTieseyi isDisnleepralp mmounnrdthoc si nueoisml o tau osn ftnra tpesroaHu. ona nguaruy ,fdetda mlrtee
Btoe. undit nseht’y e
setyyr e ehd ... |
| 27.08.2025 | QC Ware Announces 3rd Q2B Paris Conference Focused on the Roadmap to Quantum Value in Europe and Beyond, Quandela to Sponsor | QC Ware and Bpifrance to host, under the high patronage of Mr. Emmanuel MACRON, President of the French Republic, the 2025 Q2B Paris Conference to connect international and European quantum industry experts across pharmaceutical, finance, t... |
| 15.08.2025 | Elanco CEO says new products helping to turn the corner on growth | Please subscribe to IBJ to decode this article.
n"m3fs9-nuh"j=mldczto.pala"p/So.t/hgmto tehn>sda c tmfme/=o02pptsut2o"/ps0l0"g"m:d9cweto.tccf"0j_"hSetib/sgdm-3njifiwnr> jon=il s13/=/sigg3w:thl3h... |
| 04.08.2025 | Trump Demands Pharma Price Cuts: A New Era for U.S. Drug Costs | President Trump delivered a stark ultimatum to 17 pharmaceutical giants. He demands they slash U.S. drug prices to international "most favored nation" levels. Companies must commit by September 29. Failure risks severe government ... |
| 04.08.2025 | After Hengrui’s USD 500 million deal with GSK, which biotech firms are next in line? | Last month, Hengrui Pharmaceuticals announced a blockbuster licensing deal with GSK worth up to USD 12.5 billion, with an upfront payment of USD 500 million. The deal grants GSK the overseas rights to Hengrui’s HRS-9821 as well as exclusive... |
| 01.08.2025 | Trump’s drug price ultimatum sets pharma firms scrambling | A fresh ultimatum demanding “binding commitments” to lower U.S. drug prices sent pharma firms scrambling Friday.
President Trump sent letters to 17 major firms outlining the steps they must take to cut costs.
Healthcare stocks tumbled Frida... |
| 31.07.2025 | Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days | President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
On Truth Social, Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Reg... |
| 29.07.2025 | ArisGlobal Achieves Strong Global Growth and Continued Innovation in First Half 2025 | Expanding Impact of LifeSphere® NavaX™ Across the Industry, 27 Go-Lives, and New Global Pharma Adoptions
BOSTON, July 29, 2025 /PRNewswire/ -- ArisGlobal, an AI-first technology company and creator of LifeSphere®, today announced significan... |
| 22.07.2025 | BiomEdit Forges New Path in Animal Health with Major Advances and Strategic Funding | BiomEdit, a leading animal health biotechnology firm, announced major advancements. Its pioneering poultry solution, BE-101 (Optavant™), a non-antibiotic treatment for necrotic enteritis in broiler chickens, entered the final USDA condition... |
| 16.07.2025 | Animal-health startup BiomEdit advances poultry antibody, lands $20M in funding, grants | Please subscribe to IBJ to decode this article.
aEdlWuninn ele rmoaae.sto7oot elndntt ndptlruceifostananmttpmarg beo pmaoad i4niynalitra e eg$s1tiinnah natwtlt oc is iheudifmsoy o$adroeal - dieGur sis gdtihrear ged ieprah tt aesrlein o-d ee... |
| 26.06.2025 | DemeRx Appoints Biopharma Industry Veteran Vic Pirotsky to Board of Directors | Pirotsky brings more than two decades of biopharma expertise and a proven track record of leading 8+ successful new drug applications •He advocates for an "Addiction Moonshot" collaboration between government and business •Appoint... |
| 10.06.2025 | Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care | PARIS, June 10, 2025 /PRNewswire/ -- As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, the ... |
| 28.05.2025 | To develop novel therapies for cardiomyopathy, Nuevocor raised $45 M Series B funding | The Singapore-based IND-stage biotechnology startup Nuevocor, which is working to find treatments for cardiomyopathies caused by aberrant mechanobiology, has successfully closed a $45 million Series B funding round.
Nuevocor said in a state... |
| 27.05.2025 | Smile Group launches a Healthtech Venture "We're thrilled to welcome Gagandeep Singh Bedi, his rare combination of corporate leadership and deep engagement with the startup ecosystem makes him th... | Smile Group, a technology investor and operator, is launching a Healthtech Venture Builder and has appointed Gagandeep Singh Bedi as Managing Partner to lead the initiative, leveraging its full-stack approach of bringing in capital and oper... |
| 06.05.2025 | SG biotech startup Nuevocor raises $45m to help heart failure patients | Singapore-based biotech company Nuevocor has raised $45 million in a Series B funding round to advance the treatment for patients with cardiomyopathies, a form of heart disease that could lead to heart failure, according to a statement on T... |
| 30.04.2025 | ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care | Showcasing the future of ophthalmic research at ARVO 2025:
ZEISS Research Data Platform launch - a cloud-based, AI-driven technology solution designed to accelerate discoveries, integrating research and clinical data, and simplifying resear... |
| 29.04.2025 | Перечень жизненно важных лекарств не резиновый | - |
| 02.04.2025 | Latest Innovation in Automation and AI/ML Presented at the 11th Annual Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Top biopharmas and leading biotechs discuss new trends in AI/ML and share how th... |
| 02.04.2025 | ONTOFORCE Announces Enhanced Functionality in DISQOVER to Build Cohorts in Minutes | ONTOFORCE announces enhanced cohort-building functionality in DISQOVER
Life sciences companies can now maximize the value of their clinical data to conduct faster, more cost-effective hypothesis testing with DISQOVER's newly enhanced Cohort... |
| 22.03.2025 | Brainomix: £14 Million (Series C) Closed For Advancing AI Imaging In Healthcare | Brainomix, a company pioneering AI-based imaging tools in stroke and lung fibrosis, announced the completion of a £14 million ($18 million) Series C investment round. The funding round was co-led by prominent healthtech investors that inclu... |
| 21.03.2025 | Brainomix Secures £14M to Revolutionize Stroke and Lung Fibrosis Treatment | In the fast-paced world of healthcare technology, Brainomix is making waves. The Oxford-based company has just raised £14 million in Series C funding. This investment is a lifeline, aimed at expanding its reach into the U.S. market. With a ... |
| 20.03.2025 | Brainomix secures €16.7 milllion to advance its AI imaging technology in healthcare | Oxford-based Brainomix, a company pioneering AI-powered imaging tools in stroke and lung fibrosis, today announced the completion of a €16.7 million Series C investment round to expand to the U.S.
The round is co-led by prominent HealthTech... |
| 20.03.2025 | Brainomix Raises £14M in Series C Funding | Brainomix, an Oxford, UK-based company providing AI-powered imaging tools in stroke and lung fibrosis, raised £14M in Series C funding.
The round was led by co-led by Parkwalk Advisors, and the Boehringer Ingelheim Venture Fund (BIVF), alon... |
| 13.03.2025 | Generics Take Center Stage as Empagliflozin Patent Expires | The world of pharmaceuticals is often a battleground of innovation and competition. On March 11, 2025, the diabetes drug Empagliflozin, known commercially as Jardiance, stepped into a new era. The patent held by Boehringer Ingelheim (BI) ha... |
| 12.03.2025 | Day 1 after diabetes drug Empagliflozin goes off patent, generics go to town with it | Drugmakers have begun to roll-out their generic versions of diabetes drug Empagliflozin, on day one after the innovative blockbuster drug from Boehringer Ingelheim (BI) went off patent protection (March 11).
At least three domestic drugmake... |
| 12.03.2025 | Rahul Bhatia’s Role in Transforming Financial Systems with SAP | Share
Tweet
Share
Share
Email
It is often said that true development lies at the intersection of technology and business understanding. For nearly two decades, Rahul Bhatia has occupied this space, leading systems, applications, and product... |
| 07.03.2025 | Enabling careers that make a difference in patient care | Listen
7 min
New: You can now listen to articles.
This audio is generated by an AI tool.
Boehringer Ingelheim’s commitment to employee well-being and professional growth goes beyond being a workplace benefit – it’s the foundation of the pha... |
| 19.02.2025 | BluMaiden Biosciences Appoints New US-based Leadership to Accelerate Global Expansion | - Dr. Terence Kelly named interim CEO and Prof. Damian O'Connell named Chair of the Scientific Advisory Board, joins Board of Directors
- Appointment of US-based CEO completes the recent build out of BluMaiden's executive team in preparatio... |
| 29.01.2025 | Venture Kick alumni: job creation and investment strengthen Swiss economy |
The Venture Kick Annual Report 2024 highlights the continued success of the Kick Foundation initiative in solidifying Switzerland’s position as a global innovation leader. In 2024, Venture Kick experienced significant growth in startup app... |
| 18.01.2025 | Medicare's Drug Price Negotiations: A New Era for Prescription Costs | In a significant shift, Medicare is stepping into the ring to negotiate drug prices. This change aims to alleviate the financial burden on millions of seniors. The latest announcement includes 15 new drugs, bringing the total to 25. These d... |
| 17.01.2025 | Ozempic, Wegovy and other drugs are among 15 selected for Medicare’s price negotiations | That brings the total to 25 drugs that will have lower price tags for Medicare enrollees.
Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutin... |
| 16.01.2025 | Boehringer provides update on iclepertin Phase III program in schizophrenia | Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were not met.1–6 Overall, no statistically si... |
| 13.01.2025 | AbbVie’s SKYRIZI[®] (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis | AbbVie’s SKYRIZI[®] (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis
Mon, Jan 13, 2025 12:16 CET Report this content
PRESS RELEASE – For UK consumer health, medica... |
| 06.01.2025 | Executive reshuffle in four startups |
As of this year, Ulrich Harmuth is the Chief Executive Officer at betterview, which has since its inception in 2021 established itself as the market leader in refractive surgery. The company has performed over 15,000 successful treatments.... |
| 05.01.2025 | Apheris: Unlocking the Future of Life Sciences with Federated Computing | In the world of healthcare, data is gold. Yet, much of it remains buried, locked away by privacy concerns and regulatory barriers. Apheris, a Berlin-based startup, is on a mission to change that. Founded in 2019, Apheris is pioneering feder... |
| 04.01.2025 | Apheris: федеративные вычисления для преобразования медицины и фармацевтики через AI | Искусственный интеллект критически зависит от данных, однако большая часть медицинской информации остается неиспользованной из-за таких факторов, как защита конфиденциальности пациентов, нормативные ограничения и охрана интеллектуальной соб... |
| 14.12.2024 | Lupin acquires 3 anti-diabetes trademarks from Boehringer Ingelheim | Drugmaker Lupin acquires anti-diabetes trademarks Gibtulio, Gibtulio Met and Ajaduo from Boehringer Ingelheim International , strengthening its diabetes footprint in the country.
The trademark rights for these brands will be transferred to ... |
| 11.12.2024 | NaturVet strengthens leadership team with Willie Post as Executive Director of US Sales | Willie Post, the Executive Director of U.S. Sales for NaturVet.
The former Boehringer Ingelheim director has extensive experience in pet healthcare and sales leadership
TEMECULA, Calif., Dec. 11, 2024 /PRNewswire-PRWeb/ -- NaturVet announce... |
| 05.12.2024 | Refoxy Pharmaceuticals Secures €9.1 Million to Tackle Idiopathic Pulmonary Fibrosis | In the bustling world of biotechnology, where innovation meets necessity, Refoxy Pharmaceuticals has emerged as a beacon of hope. The Berlin-based company recently announced a significant funding milestone, raising €9.1 million in a seed ex... |
| 04.12.2024 | Biotech Refoxy Pharmaceuticals advances research with €9.1M funding | Biotech Refoxy Pharmaceuticals has raised €9.1 million Seed-extension financing.
The German startup is the first preclinical biotech company purposely developing small molecule activators of the FOXO3 transcription factor for the treatment ... |
| 04.12.2024 | Refoxy Pharmaceuticals Raises €9.1M in Seed Extension | Refoxy Pharmaceuticals, a Berlin, Germany-based preclinical biotech company developing small molecule activators of the FOXO3 transcription factor for the treatment of age-related diseases, raised €9.1M in Seed extension funding.
The round ... |
| 27.11.2024 | Vienna-based Springtime Technologies secures growth investment from SEP for global expansion | Springtime Technologies, an Austrian startup specialising in accounts payable automation software, has secured a “significant investment” from UK-based growth equity investor, Scottish Equity Partners (SEP). The funding will drive Springtim... |
| 27.11.2024 | Springtime Technologies Receives Strategic Growth Investment from SEP | Springtime Technologies, a Vienna, Austria-based accounts payable automation software company, received a strategic investment from Scottish Equity Partners.
The amount of the deal was not disclosed.
Led by Markus Hübl, Founder and CEO, Spr... |
| 23.11.2024 | Boehringer Ingelheim launches VETMEDIN® Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs | Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in their lifetime1
Previous studies have shown that VETMEDIN® could help improve the survival time and quality of life for dogs with co... |
| 20.11.2024 | Doo Financial's Leap into Indonesia: A New Era for Local Investors | Doo Financial has set its sights on Indonesia, marking a significant milestone in the global investment landscape. This move is not just a business expansion; it’s a bridge connecting local investors to the vast ocean of global markets. The... |
| 19.11.2024 | Boehringer Ingelheim, Red Health ambulance services collaborate on pre-hospital stroke care | Biopharmaceutical company Boehringer Ingelheim (BI) India has signed a Memorandum of Understanding with RED. Health, an emergency care venture, to strengthen emergency pre-hospital stroke care services.
The agreement includes “implementatio... |
| 18.11.2024 | Boehringer Ingelheim Commits to Veeva Vault CRM | Top biopharma company selects the next generation of CRM for life sciences as its commercial foundation for future expansion and launches
SINGAPORE, Nov. 18, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer In... |
| 11.11.2024 | Economist Impact's 4th edition Future of Health Asia to empower healthcare stakeholders by building strategies for a sustainable healthcare system, and igniting investment for an inclusive and healthi... | Members of the media are invited to register here.
SINGAPORE, Nov. 11, 2024 /PRNewswire/ -- The 4th edition Future of Health Asia today announced the confirmed speaker line-up for the 2024 event. Building on the success of three editions, F... |
| 04.11.2024 | +++ Ride +++ bao +++ Aignostics +++ neoshare +++ Series-A +++ | Was gibt’s Neues? In unserem #StartupTicker liefern wir eine kompakte Übersicht über die wichtigsten Startup-Nachrichten des Tages (Montag, 4. November) #STARTUPLAND: LEARN, CONNECT, GROW
Kommt mit ins Startupland! Es erwartet Euch eine fas... |
| 03.11.2024 | Aignostics: $34 Million (Series B) Raised To Turn Complex Pathology Data Into Transformative Insights | Aignostics – a global AI company that turns complex multi-modal pathology data into transformative insights – announced that it has raised $34 million in Series B financing. This additional funding will be used for building new product offe... |
| 29.10.2024 | Aignostics: Pioneering AI in Precision Medicine with $34 Million Boost | Aignostics, a Berlin-based artificial intelligence (AI) company, has secured $34 million in Series B funding. This significant investment is a testament to the growing confidence in AI's role in transforming healthcare. The funding round wa... |
| 29.10.2024 | Berlin-based Aignostics secures €31.4 million Series B to enhance precision medicine with AI | Aignostics, a global artificial intelligence (AI) company that turns complex multi-modal pathology data into transformative insights, announced that it has raised €31.4 million in Series B financing. This additional funding will be used to ... |
| 29.10.2024 | Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI | Investments will support new product offerings, US expansion, and development of pathology foundation models.
Aignostics, a global artificial intelligence (AI) company that turns complex multi-modal pathology data into transformative insigh... |
| 17.10.2024 | Mars Petcare's Leadership Shake-Up: A New Era for Veterinary Health and Diagnostics | In a bold move, Mars Petcare has reshuffled its leadership deck, signaling a fresh chapter for its Veterinary Health and Science & Diagnostics divisions. This change comes as the company, a titan in the pet care industry, seeks to innov... |
| 16.10.2024 | Ikerian Holds Series B Funding First Close of USD 8M | (left) Carlos Ciller, PhD, CEO, co-founder and Chairman Ikerian AG and RetinAI US Inc.; (center) Stefanos Apostolopoulos, PhD, CTO and co-founder Ikerian AG and RetinAI US Inc.; (right) Sandro De Zanet, PhD, Chief Scientific Officer and co-... |
| 16.10.2024 | USD 8M and a strategic partner for Ikerian AG |
Ikerian AG and its subsidiary, RetinAI U.S. Inc. are committed to revolutionizing the way ophthalmology clinics connect and manage patient data. Established in 2017, the company develops software solutions to accelerate clinical, research ... |
| 15.10.2024 | BioStock: Saniona achieves milestone with Boehringer Ingelheim | BioStock: Saniona achieves milestone with Boehringer Ingelheim
Tue, Oct 15, 2024 11:19 CET Report this content
Saniona’s collaboration with Boehringer Ingelheim has advanced to the lead optimization stage, triggering a 500,000 Euro research... |
| 09.10.2024 | Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment | INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–October 9, 2024–
Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal to develop a first-in-cla... |
| 08.10.2024 | Obulytix appoints Dr. Kristof Van Emelen as Chief Executive Officer | Ghent, Belgium, October 1st 2024 – Obulytix, a pre-clinical stage biotech company pioneering phage lysin-based antibiotics to fight antibiotic-resistant infections, announces the appointment of Dr. Kristof Van Emelen as its new Chief Execut... |
| 08.10.2024 | Eldico secures fresh funding to fuel global expansion |
Founded in 2019 and based at the Switzerland Innovation Park Innovaare at the Paul Scherrer Institute, ELDICO has quickly established itself as a leader in electron diffraction. The company's flagship product, the ELDICO ED-1 electron diff... |
| 25.09.2024 | Animab announces Jan Spaas as new Chairman of the Board | Zwijnaarde, Belgium – May 15, 2024: Animab, a front-runner in the field of highly innovative first-in-class oral antibody solutions for unmet needs in production animals, is excited to announce Jan Spaas joined the company’s board as Chairm... |
| 19.09.2024 | A New Dawn in Kidney Cancer Treatment: Roswell Park's Breakthrough Regimen | In the realm of cancer treatment, hope often flickers like a candle in the dark. But recent findings from Roswell Park Comprehensive Cancer Center have ignited a brighter flame for patients battling metastatic kidney cancer. At the European... |
| 19.09.2024 | 2024 ISPE Pharma 4.0™ and Annex 1 Conference Featured Speakers Are Announced | The 2024 ISPE Pharma 4.0™ and Annex 1 Conference will take place on 10-11 December in Rome, Italy, and virtually.
The 2024 ISPE Pharma 4.0™ and Annex 1 Conference will take place on 10-11 December in Rome, Italy, and virtually.
NORTH BETHES... |
| 18.09.2024 | Tech Park Basel zieht Bilanz |
Der Tech Park Basel ist seit Sommer 2011 in Betrieb. Neben den auf die Nutzung durch junge Technologieunternehmen zugeschnittenen Büro- und Laborflächen stellt der Tech Park Basel auch verschiedene Infrastrukturen bereit und bietet Dienstl... |
| 16.09.2024 | Positive clinical progress in the biotech scene |
With the dosing of its first patient for lead candidate CDR404, CDR-Life has made significant clinical progress in its M-gager® portfolio for solid tumors, marking important milestones in the company’s mission to deliver innovative, antibo... |
| 12.09.2024 | Revolutionizing Kidney Health: The Power of Technology and Community Engagement | Chronic kidney disease (CKD) is a silent predator, lurking in the shadows of public health. It affects over 35 million Americans, yet 90% remain unaware of their condition. The statistics are staggering: one in three adults is at risk, yet ... |
| 11.09.2024 | Study Conducted at Sheppard Pratt Reveals Lower Cognitive Functioning as Key Risk Factor for Natural Cause Mortality in Schizophrenia | BALTIMORE, Sept. 11, 2024 /PRNewswire/ -- JAMA Network Open recently published a first-of-its-kind study conducted at Sheppard Pratt identifying lower cognitive functioning as a significant risk factor for natural cause mortality among indi... |
